Table 3.
Dose and duration of analgesic use and risk of ESRD: All analgesics.
| Short duration | Long Duration | ||||
| Cases/controls | OR (95% CI)* | Cases/controls | OR (95% CI) * | ||
| Low dose | All analgesics | 123/580 | 0.78 (0.63–0.97) | 36/216 | 0.62 (0.43–0.89) |
| All monos together1 | 106/529 | 0.74 (0.59–0.93) | 31/200 | 0.57 (0.39–0.85) | |
| All combis together2 | 49/264 | 0.69 (0.50–0.95) | 19/84 | 0.84 (0.51–1.40) | |
| High Dose | All analgesics | 70/214 | 1.21 (0.91–1.61) | 132/582 | 0.84(0.67–1.05) |
| All monos together1 | 60/194 | 1.14 (0.84–1.55) | 117/531 | 0.82(0.65–1.03) | |
| All combis together2 | 29/88 | 1.22 (0.79–1.88) | 71/268 | 0.99 (0.74–1.33) | |
1 Cases and controls that never used mono-analgesics were not shown in this table (47 cases, 138 controls for the group "all monos"
2 Cases and controls that never used combination-analgesics were not shown in this table (193 cases, 888 controls for the group "all combis"
Unmatched analysis; index date 3 (5 years before start of dialysis); adjusted odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age, sex, country.
The cut-off point for higher/lower use and shorter/longer duration is the respective median found in controls; compared with the standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) as referent (= 1.0): 546 cases and 2030 controls.